Emergency reversal of anticoagulation: from theory to real use of prothrombin complex concentrates. A retrospective Italian experience. (odpre novo okno)

Barillari G, Pasca S, Barillari A, De Angelis V.

Vir‎: Blood Transfus 2012;10(1):87-94.

Indeksirano‎: PubMed 22044952

DOI‎: 10.2450/2011.0030-11

https://www.ncbi.nlm.nih.gov/pubmed/22044952 (odpre novo okno)

Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (odpre novo okno)

Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, Dunn AS, Kunz R; American College of Chest Physicians.

Vir‎: Chest 2012;141(2 Suppl):e326S-50S.

Indeksirano‎: PubMed 22315266

DOI‎: 10.1378/chest.11-2298

https://www.ncbi.nlm.nih.gov/pubmed/22315266 (odpre novo okno)

Pharmacological prophylaxis of bleeding in surgical patients treated with aspirin. (odpre novo okno)

Flordal PA.

Vir‎: Eur J Anaesthesiol Suppl 1997;14:38-41.

Indeksirano‎: PubMed 9088834

https://www.ncbi.nlm.nih.gov/pubmed/9088834 (odpre novo okno)

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. (odpre novo okno)

Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, Sarode R.

Vir‎: Lancet 2015;385(9982):2077-87.

Indeksirano‎: PubMed 25728933

DOI‎: 10.1016/S0140-6736(14)61685-8

https://www.ncbi.nlm.nih.gov/pubmed/25728933 (odpre novo okno)

How I treat warfarin-associated coagulopathy in patients with intracerebral hemorrhage. (odpre novo okno)

Goodnough LT, Shander A.

Vir‎: Blood 2011;117(23):6091-9.

Indeksirano‎: PubMed 21411756

DOI‎: 10.1182/blood-2010-11-316075

https://www.ncbi.nlm.nih.gov/pubmed/21411756 (odpre novo okno)

Long-term safety and efficacy of a pasteurized nanofiltrated prothrombin complex concentrate (Beriplex P/N): a pharmacovigilance study. (odpre novo okno)

Hanke AA, Joch C, Görlinger K.

Vir‎: Br J Anaesth 2013;110(5):764-72.

Indeksirano‎: PubMed 23335567

DOI‎: 10.1093/bja/aes501

https://www.ncbi.nlm.nih.gov/pubmed/23335567 (odpre novo okno)

Reversing the effects of antiplatelet agents in the setting of intracranial hemorrhage: a look at the literature. (odpre novo okno)

Jaben EA, Mulay SB, Stubbs JR.

Vir‎: J Intensive Care Med 2015;30(1):3-7.

Indeksirano‎: PubMed 25492811

DOI‎: 10.1177/0885066613487298

https://www.ncbi.nlm.nih.gov/pubmed/25492811 (odpre novo okno)

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. (odpre novo okno)

Levi M, Eerenberg E, Kamphuisen PW.

Vir‎: J Thromb Haemost 2011;9(9):1705-12.

Indeksirano‎: PubMed 21729240

DOI‎: 10.1111/j.1538-7836.2011.04432.x

https://www.ncbi.nlm.nih.gov/pubmed/21729240 (odpre novo okno)

Emergency reversal of warfarin anticoagulation. (odpre novo okno)

Lin Y, Callum J.

Vir‎: CMAJ 2010;182(18):2004.

Indeksirano‎: PubMed 21078740

DOI‎: 10.1503/cmaj.100983

https://www.ncbi.nlm.nih.gov/pubmed/21078740 (odpre novo okno)

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. (odpre novo okno)

Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G.

Vir‎: Thromb Haemost 2012;108(2):217-24.

Indeksirano‎: PubMed 22627883

DOI‎: 10.1160/TH12-03-0179

https://www.ncbi.nlm.nih.gov/pubmed/22627883 (odpre novo okno)

Recent advances in the development of specific antidotes for target-specific oral anticoagulants. (odpre novo okno)

Mo Y, Yam FK.

Vir‎: Pharmacotherapy 2015;35(2):198-207.

Indeksirano‎: PubMed 25644580

DOI‎: 10.1002/phar.1532

https://www.ncbi.nlm.nih.gov/pubmed/25644580 (odpre novo okno)

Idarucizumab for dabigatran reversal - full cohort analysis. (odpre novo okno)

Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI

Vir‎: N Engl J Med 2017;377(5):431-41.

Indeksirano‎: PubMed 28693366

DOI‎: 10.1056/NEJMoa1707278

https://www.ncbi.nlm.nih.gov/pubmed/28693366 (odpre novo okno)

Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. (odpre novo okno)

Skolnick BE, Shenouda M, Khutoryansky NM, Pusateri AE, Gabriel D, Carr ME.

Vir‎: Anesth Analg 2011;113(4):703-10.

Indeksirano‎: PubMed 21890888

DOI‎: 10.1213/ANE.0b013e318228c690

https://www.ncbi.nlm.nih.gov/pubmed/21890888 (odpre novo okno)

Oral anticoagulation in surgical procedures: risks and recommendations. (odpre novo okno)

Torn M, Rosendaal FR.

Vir‎: Br J Haematol 2003;123(4):676-82.

Indeksirano‎: PubMed 14616972

https://www.ncbi.nlm.nih.gov/pubmed/14616972 (odpre novo okno)

Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. (odpre novo okno)

Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW.

Vir‎: Blood 2012;119(9):2172-4.

Indeksirano‎: PubMed 22383791

DOI‎: 10.1182/blood-2011-11-393587

https://www.ncbi.nlm.nih.gov/pubmed/22383791 (odpre novo okno)